Ombitasvir/paritaprevir/ritonavir + dasabuvir + ribavirin in HCV genotype 1 infected patients who failed previous protease inhibitor therapy

AIM OF THE STUDY: Combination of ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin (3DDA±RBV) therapy is shown to be effective in HCV genotype 1 (GT1) infected patients. However, sparse data exist in patients who failed previous boceprevir or telaprevir based therapies. Real life efficacy an...

Descripción completa

Detalles Bibliográficos
Autores principales: Hunyady, Béla, Abonyi, Margit, Gerlei, Zsuzsanna, Gervain, Judit, Horváth, Gábor, Jancsik, Viktor, Lengyel, Gabriella, Makkai, Erzsébet, Pár, Alajos, Péter, Zoltán, Pusztay, Margit, Ribiczey, Pál, Rókusz, László, Sarrazin, Christoph, Schneider, Ferenc, Susser, Simone, Szalay, Ferenc, Tornai, István, Tusnádi, Anna, Újhelyi, Eszter, Werling, Klára, Makara, Mihály
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2018
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6000745/
https://www.ncbi.nlm.nih.gov/pubmed/29904724
http://dx.doi.org/10.5114/ceh.2018.75957

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6000745/
https://www.ncbi.nlm.nih.gov/pubmed/29904724
http://dx.doi.org/10.5114/ceh.2018.75957

Ejemplares similares